Pharma Legal, Enforcement & Alert Intelligence
Source-linked judgments, compliance and enforcement developments, and regulatory alerts.
Court Judgments & Legal Opinions
Pharma-related cases, judgments, legal opinions and precedents.
148 recordsOpen Section →02
Compliance & Enforcement
Compliance requirements, inspections, violations, enforcement actions and recalls.
27 recordsOpen Section →03
Legal / Regulatory Alerts
Important legal and regulatory developments requiring attention.
503 recordsOpen Section →
Court Judgments & Legal Opinions · 148 visible records
Supreme Court of India
Laborate Pharmaceuticals India Limited & Others v. State of Tamil Nadu
Summary: The Supreme Court reviewed a cough-syrup prosecution and a series of procedural defaults that prevented meaningful reanalysis before expiry.
Outcome / action: The prosecution was quashed because the manufacturer was not timely supplied the required sample portion, cognizance followed shelf-life expiry and the statutory Central Laboratory reanalysis right was effectively lost.
Practical impact: Send the manufacturer’s sample portion promptly and ensure cognizance and any CDL testing remain practically possible within shelf life.
Open official source →High Courts of India
Laborate Pharmaceuticals India Ltd. & Others v. State represented by the Drugs Inspector
Summary: The Madras High Court examined a substandard-drug prosecution, the timing of a reanalysis request and the asserted liability of company directors.
Outcome / action: The quashing petition was dismissed; the Court held that the prosecution should continue and that the directors could present their individual defences before the trial court.
Practical impact: Company officers should preserve evidence of their actual role, while manufacturers must exercise the statutory analyst-report challenge within the prescribed period.
Open source record →Supreme Court of India
Dinesh B. Patel & Others v. State of Gujarat & Another
Summary: The Supreme Court considered director liability in a serious public-health prosecution involving a defective medicine and distinguished a complaint containing only bald designation allegations.
Outcome / action: The appeal was dismissed; allegations linking the directors with manufacture of a medicine affected by fungal growth were sufficient for the matter to proceed, leaving their factual defence for trial.
Practical impact: Specific allegations connecting directors with manufacturing may sustain prosecution, particularly where the alleged defect presents serious public-health risk.
Open source record →High Courts of India
Samar Kumar Swain v. Subodha Kumar Nayak
Summary: The Orissa High Court reviewed convictions arising from medicines found after a retail licence had expired and the pharmacist had resigned.
Outcome / action: The revision was allowed and the retailer was acquitted because possession alone did not prove stocking for sale and, without a current licence, the specific licensed-person record duty under Section 18B was not established.
Practical impact: For Section 27(d), the prosecution must prove sale or stocking for sale; record-maintenance charges must match the statutory status and duty of the accused.
Open source record →Supreme Court of India
Medicamen Biotech Limited & Another v. Rubina Bose, Drug Inspector
Summary: The Supreme Court considered the manufacturer’s right to dispute a Government Analyst report and obtain testing by the Central Drugs Laboratory.
Outcome / action: The proceedings were set aside because delay effectively deprived the accused of the statutory opportunity to seek re-analysis before expiry of the sampled drug.
Practical impact: Track sampling, report service, shelf life and re-testing requests promptly because expiry may defeat the statutory safeguard.
Open source record →High Courts of India
Biochem Pharmaceutical & Others v. State
Summary: The Delhi High Court considered the consequences of failing to arrange Central Drugs Laboratory testing after a manufacturer challenged the Government Analyst report.
Outcome / action: The petition was allowed and the complaint was quashed because official inaction deprived the petitioners of their valuable right to obtain Central Laboratory testing after they had notified their intention to controvert the analyst report.
Practical impact: Once an intention to controvert is notified, the authority should preserve and advance the retesting process without delay.
Open source record →Other Courts & Tribunals
Dr. A. Krishna v. Research Drugs & Pharmaceuticals
Summary: The Trade Marks Registry examined competing claims to the LUDEM pharmaceutical mark, claimed dispensing use and the relevance of drug licences to bona fide commercial use.
Outcome / action: The opposition was allowed and the LUDEM application in Class 5 was refused because the applicant failed to prove prior bona fide trade use and lacked supporting drug-manufacturing and sales registrations.
Practical impact: Pharmaceutical trademark claims should be supported by lawful product manufacture or trade, dated sales evidence, regulatory licences and consistent statements of first use.
Open source record →Supreme Court of India
Amery Pharmaceuticals & Another v. State of Rajasthan
Summary: The Supreme Court examined whether sampling was invalid because a portion was not delivered directly to the manufacturer when the sample came from another person in the distribution chain.
Outcome / action: The Court explained distribution of sample portions and the circumstances in which a manufacturer may exercise the right to challenge the Government Analyst’s report.
Practical impact: Assess sampling compliance from the sampled person, disclosures under Section 18A and preservation of the Central Laboratory remedy.
Open source record →High Courts of India
Drug Controller General of India v. West Bengal Small Scale Manufacturers Association
Summary: The Calcutta High Court reviewed a challenge to a Central Government notification prohibiting specified drug combinations in the public interest.
Outcome / action: The appeal was allowed and the judgment quashing the Central Government notification was set aside; the Court upheld the challenged regulatory policy action under Section 26A.
Practical impact: Section 26A restrictions are expert regulatory policy measures and challenges should address the supporting safety material and statutory decision process.
Open source record →Supreme Court of India
State of Haryana v. Brij Lal Mittal & Others
Summary: The case concerns prosecution of a pharmaceutical company and its directors after sampled drugs were reported not of standard quality and misbranded or adulterated.
Outcome / action: The Court applied Section 34 principles governing when directors may be prosecuted; designation alone is insufficient without responsibility or involvement of the kind required by the provision.
Practical impact: Complaints against company officers should contain specific material showing business responsibility or consent, connivance or neglect.
Open source record →High Courts of India
Janmejoy Dinda v. State of Orissa
Summary: The Orissa High Court reviewed an unlicensed-drug prosecution and the category of persons bound by the manufacturer-source disclosure obligation.
Outcome / action: The conviction under Section 28 was set aside because Section 18A did not apply without proof that the accused was a manufacturer or distribution agent; the remaining sentence was reduced to the period already undergone with fine.
Practical impact: The prosecution must prove the status that triggers Section 18A; failure to disclose cannot be assumed merely from possession or unlicensed sale.
Open source record →Supreme Court of India
State of Karnataka v. Pratap Chand & Others
Summary: The Supreme Court considered liability of partners following prosecution of a firm for drug-law contraventions.
Outcome / action: The Court addressed responsibility of a partnership firm and its partners, applying the statutory requirements for individual liability.
Practical impact: Assess partner or director liability individually from actual responsibility and pleaded involvement rather than title alone.
Open source record →Drugs Inspector, Palace Road, Bangalore v. Dr. B. K. Krishnaiah & Another
Summary: The Supreme Court considered partner responsibility for stocking and selling drugs after expiry of potency.
Outcome / action: The appeal was allowed, the High Court judgment was set aside and the case was returned to the Magistrate for trial because the complaint materials and partnership deed supported a prima facie inquiry into partner responsibility.
Practical impact: Partnership documents and pleaded management responsibility can support process; final individual liability remains an evidentiary question for trial.
Open source record →Mohd. Shabir v. State of Maharashtra
Summary: The Supreme Court interpreted the expression concerning stocking drugs for sale in a prosecution involving drugs held without the required licence.
Outcome / action: The Court explained that mere possession or stocking is insufficient for the sale-related prohibition unless stocking for the purpose of sale is established.
Practical impact: Enforcement records should establish the commercial purpose connecting possession or stocking with sale.
Open source record →Swantraj & Others v. State of Maharashtra
Summary: The Supreme Court considered whether unlicensed storage of drugs intended for sale from another place amounted to stocking for sale.
Outcome / action: The Court treated storage connected with sale, including temporary storage for sale elsewhere, within the licensing prohibition.
Practical impact: Check every location used for sale-related drug storage for the required licence, even where customer sales occur elsewhere.
Open source record →